Produção Nacional
Revisado por pares
Renin-Angiotensin System and Cardiovascular Functions
2018; Lippincott Williams & Wilkins; Volume: 38; Issue: 7 Linguagem: Inglês
10.1161/atvbaha.118.311282
ISSN1524-4636
AutoresChia-Hua Wu, Shayan Mohammadmoradi, Jeff Z. Chen, Hisashi Sawada, Alan Daugherty, Hong Lü,
Tópico(s)Cardiovascular, Neuropeptides, and Oxidative Stress Research
ResumoHomeArteriosclerosis, Thrombosis, and Vascular BiologyVol. 38, No. 7Renin-Angiotensin System and Cardiovascular Functions Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBRenin-Angiotensin System and Cardiovascular Functions Chia-Hua Wu, Shayan Mohammadmoradi, Jeff Z. Chen, Hisashi Sawada, Alan Daugherty and Hong S. Lu Chia-Hua WuChia-Hua Wu From the Saha Cardiovascular Research Center (C.-H.W., S.M., J.Z.C., H.S., A.D., H.S.L.) Department of Pharmacology and Nutritional Sciences (C.-H.W., S.M., A.D., H.S.L.) , Shayan MohammadmoradiShayan Mohammadmoradi From the Saha Cardiovascular Research Center (C.-H.W., S.M., J.Z.C., H.S., A.D., H.S.L.) Department of Pharmacology and Nutritional Sciences (C.-H.W., S.M., A.D., H.S.L.) , Jeff Z. ChenJeff Z. Chen From the Saha Cardiovascular Research Center (C.-H.W., S.M., J.Z.C., H.S., A.D., H.S.L.) Department of Physiology (J.Z.C., A.D., H.S.L.), University of Kentucky, Lexington. , Hisashi SawadaHisashi Sawada From the Saha Cardiovascular Research Center (C.-H.W., S.M., J.Z.C., H.S., A.D., H.S.L.) , Alan DaughertyAlan Daugherty From the Saha Cardiovascular Research Center (C.-H.W., S.M., J.Z.C., H.S., A.D., H.S.L.) Department of Pharmacology and Nutritional Sciences (C.-H.W., S.M., A.D., H.S.L.) Department of Physiology (J.Z.C., A.D., H.S.L.), University of Kentucky, Lexington. and Hong S. LuHong S. Lu Correspondence to Hong S. Lu, MD, PhD, Saha Cardiovascular Research Center, University of Kentucky, BBSRB Room B249, 741 S Limestone, Lexington, KY 40503. E-mail E-mail Address: [email protected] From the Saha Cardiovascular Research Center (C.-H.W., S.M., J.Z.C., H.S., A.D., H.S.L.) Department of Pharmacology and Nutritional Sciences (C.-H.W., S.M., A.D., H.S.L.) Department of Physiology (J.Z.C., A.D., H.S.L.), University of Kentucky, Lexington. Originally published27 Jul 2018https://doi.org/10.1161/ATVBAHA.118.311282Arteriosclerosis, Thrombosis, and Vascular Biology. 2018;38:e108–e116Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: July 27, 2018: Previous Version of Record The renin-angiotensin system plays critical roles in maintaining normal cardiovascular functions and contributes to a spectrum of cardiovascular diseases. Classically, the renin-angiotensin system is composed of AGT (angiotensinogen), renin, angiotensin-converting enzyme (ACE), Ang II (angiotensin II), and 2 Ang II receptors (AT1 and AT2 receptors).1,2 AGT, a protein with 452 amino acids, is cleaved by renin to produce Ang I. Ang I is a decapeptide, which is then cleaved by ACE to produce Ang II. Ang II is an octapeptide, acting through binding to its receptors, AT1 and AT2 receptors. AT1 receptor is the major receptor for Ang II to regulate many physiological and pathophysiological functions.3–6 In mice, AT1 receptor has 2 subtypes, AT1a and AT1b, which have >90% sequence homology, but distinctive distributions and functions.4,7–12 AT1a receptor is important for blood pressure regulation and contributes to atherosclerosis and aortic aneurysms,5,13,14 whereas AT1b receptor has no evident contribution to these functions15 but is associated with vasculature contractility.16,17 AT2 receptor is abundant during fetal development but becomes low in most tissues after birth.18In the past 2 decades, many new components in this system have been discovered. These include ACE2, a homologue of ACE, which converts Ang II to Ang(1–7) or converts Ang I to Ang(1–9).19,20 The G protein–coupled receptor Mas1 was identified as the receptor of Ang(1–7).21This review highlights some recent publications in ATVB that have provided insights into understanding the classic components of the renin-angiotensin system and its alternative components contributing to cardiovascular functions. We will focus on effects of this hormonal system on cardiac dysfunction, hypertension, atherosclerosis, and aortic aneurysms.22–29AngiotensinogenAGT is the only known substrate of the renin-angiotensin system to produce all downstream angiotensin peptides. AGT regulates blood pressure as demonstrated by multiple mouse models, including global AGT-deficient mouse model and human AGT and renin transgenic mouse model.30–33 AGT was also implicated in atherosclerosis using a transgenic mouse model expressing both human angiotensinogen (Agt) and renin genes.34 Two recent studies have provided direct evidence that AGT regulates blood pressure and contributes to atherosclerosis through Ang II–mediated mechanisms.35,36 These studies used multiple genetic manipulations, including AGT hypomorphic mice, bone marrow transplantation, hepatocyte-specific AGT-deficient mouse model, and adeno-associated viral infection to repopulate the manipulated Agt in vivo. These studies demonstrate that hepatocyte-derived AGT is the predominant source to regulate blood pressure and promote atherosclerosis. A pharmacological approach using antisense oligoneucleotides has also opened a door to directly target AGT for preventing high blood pressure and atherosclerosis.36ReninRenin is the rate-limiting enzyme of the renin-angiotensin system and the only enzyme known to cleave AGT. These properties make renin a potentially attractive target to inhibit the renin-angiotensin cascade and improve Ang II–mediated cardiovascular dysfunctions.37,38 Inhibition of renin reduces blood pressure and atherosclerosis in animal models.6,36,39–43 Unfortunately, renin inhibitors in patients with cardiovascular diseases have not provided superior beneficial effects beyond the well-established ACE inhibitors or AT1 receptor blockers.44Despite some disappointing findings in human studies of renin inhibition, it has not discouraged research to understand renin-related mechanisms of cardiovascular diseases. The juxtaglomerular cells of the kidney are the major source of renin production and secretion. As an important organ in blood pressure regulation and cardiovascular functions, renal denervation aiming to reduce sympathetic nerve activity has drawn significant attention, although there are conflicting findings that need further research.45–48 A recent study using pigs discovered that this approach reduced blood pressure and improved cardiovascular functions through its influence on kidney-brain-heart axis with profound changes of plasma renin activity, implicating the involvement of the renal renin-angiotensin system regulation in the process.49Angiotensin-Converting EnzymesIn contrast to the rate-limiting and substrate-specific properties of renin, ACE is not sensitive to Ang II concentration changes, and it is an enzyme that cleaves not only Ang I but also many other substrates including bradykinin (a vasodilator) and N-acetyl-Ser-Asp-Lys-Pro (a hemoregulatory peptide).50–53 There is a highly consistent literature demonstrating that ACE inhibition reduces blood pressure and atherosclerosis in animal models.6,54,55 ACE inhibitors are one major class for treatment of hypertension, cardiovascular dysfunctions, and diabetic nephropathy in patients.56–60 Recent studies have also added new mechanistic insights into guiding the use of ACE inhibitors. It was found that high serum concentration of homocysteine decreased antihypertensive effect of enalapril, an ACE inhibitor, in chronic hypertensive patients.61ACE is ubiquitously present in many cell types, tissues, and organs.62,63 Leukocyte or smooth muscle cell–derived ACE contributed to atherosclerosis as demonstrated by bone marrow transplantation and cell-specific depletion of ACE, respectively, in mouse models,54,64 although their effects were less potent than pharmacological inhibition of ACE systemically.6 ACE is abundant in endothelial cells.65 However, depletion of ACE in this cell type had no effects on atherosclerosis.64 Global genetic depletion or pharmacological inhibition of ACE reduced blood pressure,6,66 but depletion of ACE in leukocyte, endothelial cells, or smooth muscle cells did not affect blood pressure.54,64 Despite a well-known enzyme discovered half century ago67,68 with impressive success of its inhibitors in clinical patients,69 it is still a long road to define mechanisms by which ACE contributes to multiple cardiovascular functions, including its cellular source that influences blood pressure regulation.Angiotensin IIAs the major bioactive peptide of the renin-angiotensin system, there are broad views of mechanistic insights into understanding how Ang II contributes to multiple cardiovascular physiological and pathophysiological functions. We provide a brief review of the following diseases published recently in ATVB. For most of these studies, the approach used was chronic subcutaneous infusion of Ang II.70,71Cardiac DysfunctionAng II induces several forms of cardiac dysfunction including hypertrophy, arrhythmia, and ventricle function failure.72,73 Basigin is a transmembrane glycoprotein that has multiple functions.74 In a mouse model of transverse aortic constriction, genetic reduction of basigin led to less cardiac hypertrophy, fibrosis, and heart failure.75 Deficiency of smooth muscle stromal interaction molecule 1, an endoplasmic reticulum Ca2+ sensor, also prevented Ang II–induced cardiac hypertrophy.76 These findings are consistent with that renin-angiotensin inhibition is crucial for improving cardiac dysfunction.HypertensionThere are many factors contributing to hypertension.77–79 Salt intake is believed to be a critical factor for high blood pressure.80 Ang II is also a well-recognized contributor to high blood pressure.81,82 However, high salt intake suppresses the renin-angiotensin system, whereas low dietary salt increases Ang II production.83,84 In accord with the paradox between salt intake and the renin-angiotensin regulation, dietary salt intake in blood pressure regulation and its consequent cardiovascular events have also been inconsistent, as reported in both human studies and animal models,85–91 implicating complex molecular mechanisms involved in salt versus Ang II–mediated hypertension and related cardiovascular dysfunctions.Batchu et al78 found that Axl, a receptor tyrosine kinase, in T lymphocytes exerted a significant role in Ang II–mediated blood pressure regulation. This finding is consistent with reports by Guzik et al92 and Norlander et al93 that T-lymphocyte–mediated immune response contributed to Ang II–induced high blood pressure, although this needs to be validated in human studies. In addition to immune cells, smooth muscle cells are a critical cell type in Ang II–mediated blood pressure regulation. Smooth muscle 22α is a cytoskeleton-associated protein in smooth muscle cells. Smooth muscle 22α deficiency in mice reduced Ang II–induced high blood pressure and senescence of vascular smooth muscle cells.93,94 These phenotypes were proposed to be associated with many mediators including p53-dependent pathway.95 Activation of the α7 subtype of nicotinic acetylcholine receptors (α7nAchR) inhibited Ang II–induced senescence in cultured vascular smooth muscle cells and wild-type mice, but not in mice with α7nAchR deficiency. This effect was associated with sirtuin 1 activity because inhibition of sirtuin 1 abrogated this effect.96 microRNA-143 and 145 are abundant in vascular smooth muscle cells and regulate myogenic tone.97 Depletion of these 2 microRNAs did not affect Ang II–induced high blood pressure but caused more severe arterial wall disruption, vascular remodeling, and inflammation.98 Another recent study identified cellular repressor of E1A-stimulated genes as a mediator of Ang II–induced vascular remodeling.99 From these recent studies, we can gather that Ang II–mediated hypertension is a complex process that involves a large spectrum of molecules and many cell types.AtherosclerosisAtherosclerosis is a complex disease involving diverse mechanisms including disordered lipoprotein metabolism, inflammation, endothelial dysfunction, reactive oxygen species, and endoplasmic reticulum stress.29,100–103 Animal models are a common tool to study these mechanisms and exploring potential therapeutic targets. For example, application of drugs using nanoparticles holds promise to optimize drug delivery and efficacy. In apolipoprotein E–deficient (Apoe−/−) mice fed a high-fat diet and infused with Ang II, nanoparticles containing pioglitazone, an antidiabetic drug that also had peroxisome proliferator–activated receptor-γ agonistic effects, was injected intravenously on a weekly basis for 4 weeks. Although pioglitazone administration did not change atherosclerotic lesion size and macrophage content, it reduced Ly-6C high monocytes, matrix metalloproteinase activity, and cathepsin activity.104In addition to mouse models, rabbits have been frequently used to study atherosclerosis. In one study, infusion of Ang II to Watanabe heritable hyperlipidemic rabbits led to high death rate (50% for Ang II 100 ng/kg per minute and 92% for Ang II 200 ng/kg per minute) because of acute myocardial infarction with coronary plaque erosion, rupture, and thrombosis.105 Because plaque rupture and thrombosis are high-risk complications in humans,106 this model would be optimal to study mechanisms related to the human disease. In another study, Honda et al107 infused Ang II to Japanese White rabbits when they were fed a high-cholesterol diet and injured using balloon catheter to femoral arteries. This procedure also led to atherothrombotic occlusions. Ezetimibe, a lipid-lowering drug used in patients, profoundly decreased this fatal pathology, providing rationale to determine its extended effects in patients.107Thoracic Aortic AneurysmsThoracic aortic aneurysms (TAA) manifest as profound dilation of the thoracic aorta, accompanied by compromise of aortic wall integrity, dissection, or rupture.108–112 Many genetic disorders are involved in this disease process including fibrillin-1,113,114 TGF (transforming growth factor)-β ligands and receptors,115–120 smooth muscle cell–specific isoforms of α-actin (encoded by Acta2), and myosin heavy chain (encoded by Myh11).109 In addition to these genetic manipulations, infusion of Ang II also leads to TAA, predominantly localized to the ascending aortic region.121–124The aortic wall is composed of the intima, media, and adventitia. Among the cell types of the aorta, smooth muscle cells are the most abundant cell type and have been the most frequently studied cell type in the development of TAA. Vascular smooth muscle cell phenotypes are associated with aortic aneurysm formation and its pathological process.Components of TGF-β signaling pathways are important for maintaining aortic wall integrity. However, its effects on TAA and abdominal aortic aneurysm (AAA) formation are controversial. Inhibition of TGF-β by neutralizing antibodies augmented aortic rupture rate and aortic dilation in both abdominal and thoracic aortic regions in Ang II–infused mice125–127 but attenuated development of TAA in a Marfan mouse model.114 To explore the conflicting findings in different mouse models and different locations of aortic aneurysms, a recent study determined mechanisms of TGF-β signaling in Ang II–induced TAA and AAA, combined with smooth muscle cell–specific TGF-β receptor 2 deficiency.128 Systemic TGF-β neutralization augmented AAA but had no effects on TAA. In contrast, smooth muscle cell–specific TGF-β receptor 2 deficiency augmented TAA but had no apparent effects on the abdominal aorta.128 This study emphasizes the distinctive mechanisms between TAA and AAA.129MicroRNA-21 was identified as a critical modulator of proliferation and apoptosis of smooth muscle cells during development of AAA. Overexpression of microRNA-21 reduced AAA, and inhibition of this microRNA augmented AAA in 2 common mouse models.130 A recent study discovered that in mice with Smad3 heterozygous background, aortic miR-21 expression was increased by Ang II infusion, and systemic microRNA-21 deletion exacerbated Ang II–induced TAA formation.131 This study, combined with studies using TGF-β receptor 2 genetically manipulated mice, provides evidence for the importance of TGF-β–mediated mechanisms in the development of TAA.In addition to components that are important for maintaining the aortic wall structure and integrity, embryonic origins of smooth muscle cells determine their phenotypes and functions. Embryonic origins of smooth muscle cells in the aorta are complex.132 A recent study provided evidence that smooth muscle cells in the ascending aortic region were derived from 2 embryonic origins, with second heart field contributing to the outer layers and cardiac neural crest for the inner medial layers.133 This study adds new insights into understanding mechanisms of TAA from an evolutionary viewpoint.134Besides critical roles of smooth muscle cells, inflammation is a feature of TAA. Contractile dysfunction in smooth muscle cells is present in aortas of patients with sporadic TAA and dissection and is associated with activation of NLRP3 (nucleotide oligomerization domain–like receptor family, pyrin domain containing 3)-caspase-1 inflammasome.135 A recent study reported that NLRP3 or caspase-1 deficiency in mice significantly reduced Ang II–induced contractile protein degradation and aortic aneurysm formation in both thoracic and abdominal aortic regions.135Abdominal Aortic AneurysmsAAA is defined as pathological dilation of the abdominal aorta. Same as individuals afflicted with TAA, aortic rupture is a fatal consequence of AAA.110,112,136,137 There are three commonly used mouse models to study AAA: perfusion of elastase into the infrarenal aorta,138 periaortic application of calcium chloride,139 or subcutaneous infusion of Ang II.70,140 Modifications of these mouse models have also provided mechanistic insights. For example, coadministration of β-aminopropionitrile with Ang II,141,142 coadministration of TGF-β–neutralizing antibody with Ang II125 or administration of TGF-β–neutralizing antibody to mice with elastase-induced AAA,25 or application of calcium chloride with phosphate-buffered saline onto the infrarenal aorta.143Hypercholesterolemia augments Ang II–induced AAA.144,145 Therefore, Apoe−/− mice and low-density lipoprotein receptor–deficient mice are the 2 commonly used mouse models for Ang II–induced AAA studies.70,71,140 Although Ang II–infused mouse model has become a popular model to study AAA, breeding mice to a hypercholesterolemic background has hampered its more broad use.146 A recent study provided a rapid approach for increasing plasma cholesterol and Ang II–induced AAA incidence in C57BL/6 mice by applying a gain-of-function mutation of mouse PCSK9 protein using an adeno-associated viral method,147 which was also frequently used in atherosclerosis studies.148–150Inflammation and extracellular matrix disruption and remodeling are important features of Ang II–induced AAA.112,145,151–154 Publications describing Ang II–induced AAA were featured in a recent ATVB Highlights,112 including molecules that promote inflammation involving not only macrophages but also T and B lymphocytes,155–164 oxidative stress,165–167 and many other factors.112,145,168In addition to extensive studies to define molecular mechanisms of AAA, some recent studies have emphasized the importance of studying sex differences.29,169–171 One study used the 4 core mouse model to generate gonadal male mice with XX or XY chromosomes. This study found that gonadal male mice with an XY chromosome complement exhibited diffuse aortic aneurysms, whereas XX chromosome complement exhibited focal aortic dilation. Orchiectomy attenuated Ang II–induced TAA and AAA in male mice.172Angiotensin II ReceptorsAT1a ReceptorAT1a receptor, a subtype of Ang II receptor, is the major receptor for Ang II–mediated cardiovascular functions in mice. Global deficiency of AT1a receptor ablates atherosclerosis and attenuates Ang II–induced TAA and AAA.5,14,39,173,174 This effect was not attributed to the presence of AT1a receptor on leukocytes39,174 or smooth muscle cells,14,122 whereas endothelial cell–specific depletion of AT1a receptor had modest protective effects on Ang II–induced TAA but not AAA and atherosclerosis.14,122 In agreement with these previous studies, using a well-established Marfan mouse model with genetic disruption of fibrillin-1 expression, Galatioto et al175 found that endothelial cell–specific deletion, but not smooth muscle cell–specific deficiency, of AT1a receptor modestly attenuated TAA development and related aortic rupture.AT2 ReceptorAlthough AT2 receptor remains low in most tissues and organs postnatally, many studies have reported increased presence of AT2 receptor under certain pathophysiological conditions as reviewed in a recent article.176 Genetic deletion of AT2 receptor in mice had no effects on general health and development177 but promoted angiogenesis within ischemic muscle.178 A diabetic mouse model with a spontaneous mutation in the insulin 2 gene (Ins2+/C96Y) was bred with AT2 receptor–deficient mouse model. Hindlimb ischemia was induced by ligating femoral artery. Depletion of AT2 receptor augmented blood flow reperfusion and collateral vessel formation that were associated with SH2 domain-containing phosphatase 1 activity and vascular endothelial growth factor action.179Alternative PathwaysThis section introduces an enzyme, a bioactive peptide, and a receptor beyond the classic renin–angiotensin components.Angiotensin-Converting Enzyme 2ACE2 prevents atherosclerosis and aortic aneurysms, as demonstrated by deficiency of ACE2 accelerating atherosclerosis and Ang II–induced AAA in hypercholesterolemic mice.180,181 Recently, Moran et al182 reported that ACE2 deficiency in Apoe−/− mice augmented incidence of AAA and aortic rupture rate. Of note, deficiency of ACE2 also led to spontaneous AAA formation in the absence of Ang II. Resveratrol, a class of compounds produced by many plants, increased ACE2 and inhibited AAA growth in Ang II–infused mice.Angiotensin (1–7) and Mas1Recent studies have implicated that Ang(1–7) has protective effects on multiple cardiovascular functions through its interaction with Mas1.183 Many studies reported that Ang(1–7)/Mas1-mediated actions counteracted actions of Ang II.180,184–186 For example, Ang(1–7) had vasodilation effect that was mediated by Mas1, whereas Ang II had potent vasoconstriction effect.187 One study reported that Ang(1–7)-induced NO-mediated vasodilation and increased telomerase activity of endothelial cells.187 In another study, low dose of Ang(1–7) increased angiogenesis and vasodilation through its interaction with Mas1, which had equivalent effects as same low dose of Ang II. Among potential mechanisms, ERK1/2 was essential for Ang(1–7)-induced angiogenesis and vasodilation.186,188SummaryAlthough the major renin-angiotensin members were discovered more than a half century ago, this system still attracts a large number of research work in different fields. This implicates the importance of this hormonal system in physiological and pathophysiological functions but also notes that there are many unknowns and conundrums of this system in our knowledge that require more extensive research work.Sources of FundingOur research work was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under award numbers R01HL133723 and R01HL139748 and the American Heart Association SFRN in Vascular Disease (18SFRN33960001). J.Z. Chen is supported by the National Center for Advancing Translational Sciences (UL1TR001998). H. Sawada is supported by an AHA postdoctoral fellowship (18POST33990468). The content in this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.DisclosuresNone.Footnotes*These authors contributed equally to this article.Correspondence to Hong S. Lu, MD, PhD, Saha Cardiovascular Research Center, University of Kentucky, BBSRB Room B249, 741 S Limestone, Lexington, KY 40503. E-mail hong.[email protected]eduReferences1. Wu C, Lu H, Cassis LA, Daugherty A. Molecular and pathophysiological features of angiotensinogen: a mini review.N Am J Med Sci (Boston). 2011; 4:183–190.CrossrefMedlineGoogle Scholar2. Lu H, Cassis LA, Kooi CW, Daugherty A. Structure and functions of angiotensinogen.Hypertens Res. 2016; 39:492–500. doi: 10.1038/hr.2016.17.CrossrefMedlineGoogle Scholar3. Ito M, Oliverio MI, Mannon PJ, Best CF, Maeda N, Smithies O, Coffman TM. Regulation of blood pressure by the type 1A angiotensin II receptor gene.Proc Natl Acad Sci USA. 1995; 92:3521–3525.CrossrefMedlineGoogle Scholar4. Oliverio MI, Best CF, Kim HS, Arendshorst WJ, Smithies O, Coffman TM. Angiotensin II responses in AT1A receptor-deficient mice: a role for AT1B receptors in blood pressure regulation.Am J Physiol. 1997; 272(4pt 2):F515–F520. doi: 10.1152/ajprenal.1997.272.4.F515.MedlineGoogle Scholar5. Daugherty A, Rateri DL, Lu H, Inagami T, Cassis LA. Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor.Circulation. 2004; 110:3849–3857. doi: 10.1161/01.CIR.0000150540.54220.C4.LinkGoogle Scholar6. Lu H, Balakrishnan A, Howatt DA, Wu C, Charnigo R, Liau G, Cassis LA, Daugherty A. Comparative effects of different modes of renin angiotensin system inhibition on hypercholesterolaemia-induced atherosclerosis.Br J Pharmacol. 2012; 165:2000–2008. doi: 10.1111/j.1476-5381.2011.01712.x.CrossrefMedlineGoogle Scholar7. Burson JM, Aguilera G, Gross KW, Sigmund CD. Differential expression of angiotensin receptor 1A and 1B in mouse.Am J Physiol. 1994; 267(2pt 1):E260–E267. doi: 10.1152/ajpendo.1994.267.2.E260.MedlineGoogle Scholar8. Gasc JM, Shanmugam S, Sibony M, Corvol P. Tissue-specific expression of type 1 angiotensin II receptor subtypes. An in situ hybridization study.Hypertension. 1994; 24:531–537.LinkGoogle Scholar9. Sugaya T, Nishimatsu S, Tanimoto K, Takimoto E, Yamagishi T, Imamura K, Goto S, Imaizumi K, Hisada Y, Otsuka A. Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia.J Biol Chem. 1995; 270:18719–18722.CrossrefMedlineGoogle Scholar10. Chen X, Li W, Yoshida H, Tsuchida S, Nishimura H, Takemoto F, Okubo S, Fogo A, Matsusaka T, Ichikawa I. Targeting deletion of angiotensin type 1B receptor gene in the mouse.Am J Physiol. 1997; 272(3pt 2):F299–F304. doi: 10.1152/ajprenal.1997.272.3.F299.MedlineGoogle Scholar11. Zhu Z, Zhang SH, Wagner C, Kurtz A, Maeda N, Coffman T, Arendshorst WJ. Angiotensin AT1B receptor mediates calcium signaling in vascular smooth muscle cells of AT1A receptor-deficient mice.Hypertension. 1998; 31:1171–1177.LinkGoogle Scholar12. Oliverio MI, Kim HS, Ito M, Le T, Audoly L, Best CF, Hiller S, Kluckman K, Maeda N, Smithies O, Coffman TM. Reduced growth, abnormal kidney structure, and type 2 (AT2) angiotensin receptor-mediated blood pressure regulation in mice lacking both AT1A and AT1B receptors for angiotensin II.Proc Natl Acad Sci USA. 1998; 95:15496–15501.CrossrefMedlineGoogle Scholar13. Crowley SD, Gurley SB, Coffman TM. AT(1) receptors and control of blood pressure: the kidney and more.Trends Cardiovasc Med. 2007; 17:30–34. doi: 10.1016/j.tcm.2006.11.002.CrossrefMedlineGoogle Scholar14. Rateri DL, Moorleghen JJ, Balakrishnan A, Owens AP, Howatt DA, Subramanian V, Poduri A, Charnigo R, Cassis LA, Daugherty A. Endothelial cell-specific deficiency of Ang II type 1a receptors attenuates Ang II-induced ascending aortic aneurysms in LDL receptor-/- mice.Circ Res. 2011; 108:574–581. doi: 10.1161/CIRCRESAHA.110.222844.LinkGoogle Scholar15. Poduri A, Owens AP, Howatt DA, Moorleghen JJ, Balakrishnan A, Cassis LA, Daugherty A. Regional variation in aortic AT1b receptor mRNA abundance is associated with contractility but unrelated to atherosclerosis and aortic aneurysms.PLoS One. 2012; 7:e48462. doi: 10.1371/journal.pone.0048462.CrossrefMedlineGoogle Scholar16. Zhou Y, Chen Y, Dirksen WP, Morris M, Periasamy M. AT1b receptor predominantly mediates contractions in major mouse blood vessels.Circ Res. 2003; 93:1089–1094. doi: 10.1161/01.RES.0000101912.01071.FF.LinkGoogle Scholar17. Owens AP, Subramanian V, Moorleghen JJ, Guo Z, McNamara CA, Cassis LA, Daugherty A. Angiotensin II induces a region-specific hyperplasia of the ascending aorta through regulation of inhibitor of differentiation 3.Circ Res. 2010; 106:611–619. doi: 10.1161/CIRCRESAHA.109.212837.LinkGoogle Scholar18. Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors.J Biol Chem. 1993; 268:24539–24542.CrossrefMedlineGoogle Scholar19. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9.Circ Res. 2000; 87:E1–E9.LinkGoogle Scholar20. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase.J Biol Chem. 2000; 275:33238–33243. doi: 10.1074/jbc.M002615200.CrossrefMedlineGoogle Scholar21. Santos RA, Simoes e Silva AC, Maric Cet al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas.Proc Natl Acad Sci USA. 2003; 100:8258–8263. doi: 10.1073/pnas.1432869100.CrossrefMedlineGoogle Scholar22. Goldberg IJ. 2017 George Lyman Duff Memorial Lecture: fat in the blood, fat in the artery, fat in the heart: triglyceride in physiology and disease.Arterioscler Thromb Vasc Biol. 2018; 38:700–706. doi: 10.1161/ATVBAHA
Referência(s)